Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2966938 | 0.92 | ALOX5 (0.50) | ALOX5ALDH1A1TSHRTHRBEPHX1 | |
| SCHEMBL2961154 | 0.92 | ALOX5 (0.50) | ALOX5ALDH1A1TSHRTHRBEPHX1 | |
| SCHEMBL11468983 | 0.90 | ALOX5 (0.43) | ALOX5ALDH1A1TSHRTHRBEPHX1 | |
| SCHEMBL1476747 | 0.85 | ALOX5 (0.55) | ALOX5ALDH1A1TSHRTHRBEPHX1 | |
| SCHEMBL1476715 | 0.85 | ALOX5 (0.55) | ALOX5ALDH1A1TSHRTHRBEPHX1 | |
| SCHEMBL19692314 | 0.85 | ALOX5 (0.55) | ALOX5ALDH1A1TSHRTHRBEPHX1 | |
| SCHEMBL1611049 | 0.85 | ALOX5 (0.55) | ALOX5ALDH1A1TSHRTHRBEPHX1 | |
| SCHEMBL19691908 | 0.85 | ALOX5 (0.55) | ALOX5ALDH1A1TSHRTHRBEPHX1 | |
| SCHEMBL4812718 | 0.85 | — | — | |
| SCHEMBL7107196 | 0.83 | ALOX5 (0.52) | ALOX5ALDH1A1TSHRTHRBEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10882831-B2 | Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same | THE UNIVERSITY OF TOLEDO (US) | 2021-01-05 | — | — | US | claimed |
| CN-106543083-B | A kind of absorption film-forming type imidazoline inhibitor and preparation method thereof | 中海油天津化工研究设计院有限公司 | 2019-06-25 | — | — | CN | disclosed |
| CN-103833979-A | Bitriselenophen-benzodi(benzoselendiazole) copolymer, preparation method and application thereof | OCEANS KING LIGHTING SCIENCE | 2014-06-04 | — | — | CN | disclosed |
| CN-103833973-A | Copolymer containing dithieno (3,2-b:2',3'-d) thiophene-silole (2,3-b:3',2'-d) (diazosulfide) as well as preparation method and application of copolymer | OCEANS KING LIGHTING SCIENCE | 2014-06-04 | — | — | CN | disclosed |
| CN-102417585-B | Organic semiconductor material containing dithienothiophene and thienopyrryldiketone units, and preparation method and application thereof | Haiyangwang Lighting Technology Co., Ltd. (CN) | 2013-10-02 | — | — | CN | disclosed |
| CN-102417585-A | Organic semiconductor material containing dithienothiophene and thienopyrryldiketone units, and preparation method and application thereof | OCEANS KING LIGHTING SCIENCE | 2012-04-18 | — | — | CN | disclosed |
| US-20090275779-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BENZYLAMINE DERIVATIVE | KANEKA CORPORATION (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1942103-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BENZYLAMINE DERIVATIVE | Kaneka Corporation (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275779-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BENZYLAMINE DERIVATIVE | SMS, SRM, ABHD5 | ALOX5 378/4885ALDH1A1 701/4885TSHR 3053/4885 |
| US-10882831-B2 | Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same | TFEB, BECN1, SQSTM1 | ALOX5 1662/4885ALDH1A1 4757/4885TSHR 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.